Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


University of Oslo

Latest From University of Oslo

Tech Transfer Roundup: Tonix Inks Trio Of COVID-19-Focused Deals

New York biotech is partnering with researchers at Columbia, Kansas State and Southern Research to address the pandemic.

Tech Transfer Round-Up Deals

Vaccibody AS

Vaccibody AS’ platform can develop vaccines that can drive the immune response in specific directions and thus optimize the vaccine for different diseases – for example, toward the T-cell cell-mediated response for therapeutic vaccines, or the B-cell antibody-mediated response for prophylactic vaccines. The start-up’s lead vaccine is a therapeutic one, targeting precancerous lesions and malignancies in the cervix caused by human papillomavirus. Safety and toxicity studies are under way, and clinical trials are planned for early 2014.


Serodus AS

The project that prompted the formation of Serodus AS is no longer the driving force of this start-up company. But the founding research did spark a deal that brought the firm a similar but more advanced asset, now one of three the firm is developing for cardiovascular indications ranging from high systolic blood pressure to atrial fibrillation to heart failure. Serodus in-licensed its lead candidate, a peptide classified as an opioid receptor agonist from Zealand Pharma, which took the compound through several clinical trials in both acute and chronic heart failure. Serodus thinks it could potentially develop a 5-HT-4 receptor antagonist it calls SER102 for atrial fibrillation that occurs in connection with surgery.


Recent Tech Transfer Deals, April 2012

START-UP ’s monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Academic and Research Institutions